Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 188,888 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total transaction of $2,368,655.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Thursday, April 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36.
• On Wednesday, March 20th, Andrew Dudum sold 50,361 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.34, for a total value of $822,898.74.
• On Tuesday, February 13th, Andrew Dudum sold 97,208 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.58, for a total value of $931,252.64.

Hims & Hers Health Stock Performance

HIMS stock opened at $11.25 on Friday. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $17.16. The firm’s 50-day moving average price is $13.97 and its two-hundred day moving average price is $10.22.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business’s revenue for the quarter was up 47.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.05) earnings per share. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter worth $48,000. Belpointe Asset Management LLC purchased a new position in Hims & Hers Health in the third quarter worth about $76,000. EMC Capital Management raised its holdings in Hims & Hers Health by 80.0% during the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after buying an additional 5,332 shares during the period. Certuity LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth about $109,000. Finally, Corton Capital Inc. bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $122,000. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Truist Financial upped their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Wednesday, February 28th. Piper Sandler raised their price target on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. Finally, Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective for the company. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.85.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.